Aspartate proteases of Candida fungi - a potential target for anti-virulent therapy

Chebotar' I.V.

doi:https://doi.org/

Chebotar' I.V.

GOU VPO Nizhegorodskaia gosudarstvennaia meditsinskaia akademiia Minzdravsotsrazvitiia RF, Nizhniĭ Novgorod

Aspartate proteases of Candida fungi - a potential target for anti-virulent therapy

Authors:

Chebotar' I.V.

More about the authors

Journal: Russian Journal of Clinical Dermatology and Venereology. 2012;10(1): 33‑38

Read: 2051 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Chebotar' IV. Aspartate proteases of Candida fungi - a potential target for anti-virulent therapy. Russian Journal of Clinical Dermatology and Venereology. 2012;10(1):33‑38. (In Russ.)

Подписка 2026 Клиническая дерматология и венерология (Russian Journal of Clinical Dermatology and Venereology)

Использование инфографики авторами научных работ

References:

Sergeev A.Yu., Sergeev Yu.V. Kandidoz. Priroda infektsii, mekhanizmy agressii i zashchity, laboratornaya diagnostika, klinika i lechenie. M: Triada-X 2001; 472.
Abad-Zapatero S., Goldman R., Muchmore S.W. et al. Structure of a secreted aspartic protease from C. albicans complexed with a potent inhibitor: Implications for the design of antifungal agents. Protein Sci 1996; 5: 4: 640-652.
Angiolella L., De Bernardis F., Bromuro C. et al. The effect of antimycotics on secretory acid proteinase of Candida albicans. J Chemother 1990; 2: 1: 55-61.
Barelle C.J., Duncan V.M.S., Brown A.J.P. et al. Azole antifungals induce up-regulation of SAP4, SAP5 and SAP6 secreted proteinase genes in filamentous Candida albicans cells in vitro and in vivo. J Antimicrob Chemother 2008; 61: 2: 315-322.
Beausejour A., Grenier D., Goulet J. P., Deslauriers N. Proteolytic activation of the interleukin-1 beta precursor by Candida albicans. Infect Immun 1998; 66: 2: 676-681.
Borelli C., Ruge E., Lee J.H. et al. X-ray structures of Sap1 and Sap5: structural comparison of the secreted aspartic proteinases from Candida albicans. Proteins 2008; 72: 4: 1308-1319.
Cassone A., De Bernardis F., Torosantucci A. et al. In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors. J Infect Dis 1999; 180: 2:453-488.
Colina A.R., Aumont F., Deslauriers N. et al. Evidence for degradation of gastrointestinal mucin by Candida albicans secretory aspartyl proteinase. Infect Immun 1996; 64: 11: 4514-4519.
Copping V.M., Barelle C.J., Hube B. et al. Exposure of Candida albicans to antifungal agents affects expression of SAP2 and SAP9 secreted proteinase genes. J Antimic Chemother 2005; 55: 5: 645-654.
Costerton J.W., Stewart P.S., Greenberg E.P. Bacterial biofilms: a common cause of persistent infections. Science 1999; 284: 1318-1322.
De Bernardis F., Cassone A. Comparison of the effects of fenticonazole and econazole on the aspartic proteinase secreted by Candida albicans. Contracept Fertil Sex 1996; 24: 2: 163-165.
De Bernardis F., Boccanera M., Adriani D. et al. Protective role of antimannan and anti-aspartyl proteinase antibodies in an experimental model of Candida albicans vaginitis in rats. Infect Immun 1997; 65: 8: 3399-3405.
Fallon K., Bausch K., Noonan J. et al. Role of aspartic proteases in disseminated Candida albicans infection in mict. Infect Immun 1997; 65: 2: 551-556.
Germaine G.R., Tellefson L.M. Effect of pH and human saliva on protease production by Candida albicans. Infect Immun 1981; 31: 323-326.
Goldman R.C., Frost D.J., Capobianco J.O. et al. Antifungal drug targets: Candida secreted aspartyl protease and fungal wall beta-glucan synthesis. Infect Agents Dis 1995; 4: 4: 228-247.
Hube B. Candida albicans secreted aspartyl proteinases. Curr Top Med Mycol 1996; 7: 1: 55-69.
Kaminishi H., Miyaguchi H., Tamaki T. et al. Degradation of humoral host defense by Candida albicans proteinase. Infect Immun 1995; 63: 3: 984-988.
Korting H.C., Schaller M., Eder G. et al. Effects of the human immunodeficiency virus (HIV) proteinase inhibitors saquinavir and indinavir on in vitro activities of secreted aspartyl proteinases of Candida albicans isolates from HIV-infected patients. Antimicrob Agents Chemoter 1999; 43: 8: 2038-2042.
Lermann U., Morschhauser J. Secreted aspartic proteases are not required for invasion of reconstituted human epithelia by Candida albicans. Microbiology 2008; 154: Pt 11: 3281-3295.
Mendes A., Mores A.U., Carvalho A.P. et al. Candida albicans biofilms produce more secreted aspartyl protease than the planktonic cells. Biol Pharm Bull 2007; 30: 9: 1813-1815.
Milewski S., Mignini F, Covelli I, Borowski E. Specific inhibition of acid proteinase secretion in Candida albicans by Lys-Nva-FMDP. J Med Vet Mycol 1994; 32: 1: 1-11.
Naglik J.R., Challacombe S.J., Hube B. Candida albicans secreted aspartyl proteinases in virulence and pathogenesis. Microbiol Mol Biol Rev 2003; 67: 3: 400-428.
Pichova I., Pavlickova L., Dostal J. et al. Secreted aspartic proteases of Candida albicans, Candida tropicalis, Candida parapsilosis and Candida lusitaniae. Inhibition with peptidomimetic inhibitors. Eur J Biochem 2001; 268: 9: 2669-2677.
Rüchel R., Boning B. Detection of Candida proteinase by enzyme immunoassay and interaction of the enzyme with alpha-2-macroglobulin. J Immunol Methods 1983; 61: 1: 107-116.
Schaller M., Korting H.C., Borelli C. et al. Candida albicans-secreted aspartic proteinases modify the epithelial cytokine response in an in vitro model of vaginal candidiasis. Infect Immun 2005; 73: 5: 2758-2765.
Schaller M., Schackert C., Korting H.C. et al. Invasion of Candida albicans correlates with expression of secreted aspartic proteinases during experimental infection of human epidermis. J Invest Dermatol 2000; 114: 4: 712-717.
Szecsi P.B. The aspartic proteases. Scand J Clin Lab Invest 1992; 210: Suppl: 5-22.
Tsushima H., Mine H., Kawakami Y. et al. Candida albicans aspartic proteinase cleaves and inactivates human epidermal cysteine proteinase inhibitor, cystatin A. Microbiology 1994; 140: Pt 1: 167-171.